Antiplatelet therapy in secondary stroke prevention

Bibliography

• PETERS KD, KOCHANEK KD, MURPHY SL: Deaths: final data for 1996. Natl. Vital. Stat. Rep. (1998) 47:1–100.
   PubMedGoogle Scholar
• BRODERICK J, BROTT T, KOTHARI R et al.: The greater Cincinnati/northern Kentucky stroke study: preliminary first-ever and total incidence rates of stroke among blacks. Stroke (1998) 29:415–421.
   PubMed Web of Science ®Google Scholar
• MATCHER DB, DUNCAN PW: Cost ofstroke. Stroke: Clinical Updates (1994) 5:9–12.
   Google Scholar
• RAGLAND DR, BUFFLER PA, REIGOLD AL, SYME SL, BUFFLER ML: Disease and injury in California with projections to the year 2007. Implications for medical education. Western j Med. (1998) 168(5):378–399.
   PubMedGoogle Scholar
• SARTI C, TUOMILEHTO J, SIVENIUS J et al.: Declining trends in incidence, case-fatality and mortality of stroke in three geographic areas of Finland during 1983-1989. Results from the FINMONICA stroke register.j Cliii. Epidemiol . (1994) 47(11):1259–1269.
   Google Scholar
• STEGMAYR B, ASPLUND K, KUULASMAA K etal.: Stroke incidence and mortality correlated to stroke risk factors in the WHO MONICA project. An ecological study of 18 populations. Stroke (1997) 28:1367–1374.
   Google Scholar
• STEGMAYR B, VINOGRADOVA T, MALYUTINA S etal.: Widening gap of stroke between east and west. Eight-year trends in occurrence and risk factors in Russia and Sweden. Stroke (2000) 31:2–8.
   Google Scholar
• AMERICAN HEART ASSOCIATION: 2001 Heart and stroke statistical update. Dallas, Texas: American Heart Association (2000).
   Google Scholar
• EASTON JD, HAUSER SL, MARTIN JB: Cerebrovascular diseases. In: Harrison's Principles of Internal Medicine (14th Edition). Fauci AS (Ed.), McGraw-Hill (1998):1006–1013.
   Google Scholar
• KRONMAL RA, HART RG, MANOLIO TA et al: Aspirin use and incident stroke in the Cardiovascular Health Study. Stroke (1998) 29:887–894.
   PubMed Web of Science ®Google Scholar
• ANTIPLATELET TRIALISTS' COLLABORATION: Collaborative overview of randomised trials of antiplatelet therapy: I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med. J. (1994) 308:81–106.
   Google Scholar
• SWEDISH ASPIRIN LOW-DOSE TRIAL(SALT) COLLABORATIVE GROUP: Swedish aspirin low-dose trial (SALT) of 75mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet (1991) 338:1345–1349.
   PubMedGoogle Scholar
• THE DUTCH TIA TRIAL STUDY GROUP: A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl. J Med. (1991) 325:1261–1266.
   Google Scholar
• TAYLOR DW, BARNETT HJ, HAYNES RB et al.: Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial: ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Lancet (1999) 353:2179–2184.
   PubMed Web of Science ®Google Scholar
• DEPARTMENT OF HEALTH AND HUMAN SERVICES/FOOD AND DRUG ADMINISTRATION: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use; final rule for professional labeling of aspirin, buffered aspirin, and aspirin in combination with antacid drug products. Fed. Reg. (1998) 63:56803–56806.
   Google Scholar
• ALBERS GW, AMARENCO P, EASTON JD et al.: Antithrombotic and thrombolytic therapy for ischemic stroke. Chest (2001) 119:300S–302S.
   Google Scholar
• HART RG, HALPERIN JL: Atrial fibrillation and stroke. Stroke (2001) 32:803–808.
   PubMed Web of Science ®Google Scholar
• PENGO V, ZASSO A, BARBERO F et al.:Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation. Am. j Cardial. (1998) 82:433–437.
   Google Scholar
• SAVI P, LAPLACE MC, MAFFRAND JP etal.: Binding of [31-1]-2-methylthio ADP to rat platelets-effect of clopidogrel and ticlopidine. I Pharmacal. Exp. Ther. (1994) 269:772–777.
   Google Scholar
• GROTTA JC, NORRIS JW, KAMM B: Prevention of stroke with ticlopidine: who benefits most? TASS Baseline and Angiographic Data Subgroup. Neurology (1992) 42(1):111–115.
   PubMedGoogle Scholar
• GENT M, BLAKELY JA, EASTON JD et al.: The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet (1989) 2:442–443.
   Google Scholar
• SHARIS PJ, CANNON CP, LOSCALZO J: The antiplatelet effects of ticlopidine and clopidogrel. Ann. Intern. Med. (1998) 129:394–405.
   PubMed Web of Science ®Google Scholar
• BENNETT CL, WEINBERG PD. ROZENBERG-BEN-DOR K etal.: Thrombotic thrombocytopenic purpura associated with ticlopidine use: a report of 3 cases and review of the literature. Arch. Intern. Med. (1999) 159:311–314.
   Google Scholar
• WEISBERG LA FOR THE TICLOPIDINE ASPIRIN STROKE STUDY GROUP: The efficacy and safety of ticlopidine and aspirin in non-whites: analysis of a patient subgroup from the Ticlopidine and Aspirin Stroke Study. Neurology (1993) 43:27–31.
   PubMedGoogle Scholar
• CAPRIE STEERING COMMITTEE: A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet (1996) 348:1329–1339.
   PubMed Web of Science ®Google Scholar
• BENNETT CL, CONNORS JM, CARWILE JM etal.: Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl. j Med. (2000) 342:1773–1777.
   Google Scholar
• MULLER TH, BINDER K, GUTH BD: Pharmacology of current and future antithrombotic therapies. Cardial. CM]. (1994) 12:411–442.
   Google Scholar
• MONCADA D, KORBUT R: Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Lancet (1978) 1:1286–1289.
   PubMed Web of Science ®Google Scholar
• DIENER HC, CUNHA L, FORBES C et al.: Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke: European Stroke Prevention Study 2. Neural Li. (1996) 143:1–13.
   Google Scholar
• THE SYMPHONY INVESTIGATORS: Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. Lancet (2000) 355:337–345.
   PubMed Web of Science ®Google Scholar
• HEESCHEN C, HAMM CW: Difficulties with oral platelet glycoprotein IIb/IIIa receptor antagonists. Lancet (2000) 355:330–331.
   PubMed Web of Science ®Google Scholar
• PETER K, SCHWARZ M, YLANNE J et al.: Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (aII603) inhibitors. Blood (1998) 92:3240–3249.
   PubMed Web of Science ®Google Scholar
• TOPOL EJ, EASTON JD, AMARENCO P et al.: Design of the blockade of the glycoprotein Iib/IIIa receptor to avoid vascular occluion (BRAVO) trial. Am. Heart (2000) 139:927–933.
   PubMed Web of Science ®Google Scholar
• BERTRAND ME, RUPPRECHT HJ, URBAN P etal.: Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin after coronary stenting. The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation (2000) 102:624–629.
   Google Scholar
• EASTON JD: Future perspectives for optimizing oral antiplatelet therapy. Cerebrovascular Diseases (2001) 11:23–28.
   PubMedGoogle Scholar
• BOGOUSSLAVSKY J: Benefit of ADP receptor antagonists in atherotrhombotic patients: new evidence. Cerebrovascular Diseases (2001):5–10.
   PubMedGoogle Scholar